Literature DB >> 22792711

[The analysis of biochemical markers of MCF-7 cells apoptosis induced by recombinant analog of lactaptin].

A S Fomin, O A Koval', D V Semenov, M O Potapenko, E V Kuligina, Iu Ia Kit, V A Rikhter.   

Abstract

Earlier we isolated and characterized human milk pro-apoptotic peptide - lactaptin and generated its engineered analog - RL2. It was shown that both lactaptin and RL2 are capable to induce apoptotic death of MCF-7 cells. In this report we have analyzed biochemical markers of RL2 induced MCF-7 apoptosis. The activation of initiator and effector caspases as well as mitochondrial membrane potential and cytoplasm membrane changes were analyzed using flow cytometry and Western-blot methods. We have found that RL2 induced apoptotic death of MCF-7 cells was accompanied by PS exposure on the plasma membrane surface. It also was shown that RL2 has induced dissipation of mitochondrial membrane potential and resulted in activation of initiator caspases 8, 9 and effector caspase 7.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22792711     DOI: 10.1134/s1068162012010086

Source DB:  PubMed          Journal:  Bioorg Khim        ISSN: 0132-3423


  3 in total

1.  Selection of antitumor displayed peptides for the specific delivery of the anticancer drug lactaptin.

Authors:  Anna Andreevna Nemudraya; Elena Vladimirovna Kuligina; Alexandr Alexeevich Ilyichev; Alexandr Sergeevich Fomin; Grigory Alexandrovich Stepanov; Anna Valentinovna Savelyeva; Olga Alexandrovna Koval; Vladimir Alexandrovich Richter
Journal:  Oncol Lett       Date:  2016-10-14       Impact factor: 2.967

2.  Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.

Authors:  Galina Kochneva; Galina Sivolobova; Anastasiya Tkacheva; Antonina Grazhdantseva; Olga Troitskaya; Anna Nushtaeva; Anastasiya Tkachenko; Elena Kuligina; Vladimir Richter; Olga Koval
Journal:  Oncotarget       Date:  2016-11-08

3.  The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.

Authors:  N S Vasileva; A B Ageenko; V A Richter; E V Kuligina
Journal:  Acta Naturae       Date:  2022 Apr-Jun       Impact factor: 2.204

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.